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Since the foundation of the Journal of Venomous Animals
and Toxins including Tropical Diseases in 1995, special
attention has been given to the publication of results
from research studies on products developed from animal
toxins [1,2]. For years, proteins, enzymes and peptides
have been isolated and synthesized in the search for new
medications and target molecules. The serine proteases
extracted from snake venom were selected as molecules
of interest since they act on human and animal hemo-
static systems, by the thrombin-like enzymes, converting
fibrinogen into fibrin [1,2].
About 20 years ago the researchers of the Center for
the Study of Venoms and Venomous Animals (CEVAP)
at UNESP proposed to engage in prospecting for a
new sealant from a serine protease extracted from the
venom of Crotalus durissus terrificus associated with a
fibrinogen-rich cryoprecipitate and coagulation factors
extracted from buffalos [1,3,4]. For medicinal application,
this new sealant does not present risk of transmission
of infectious diseases, is cheaper on account of being a
genuinely Brazilian product, is standardized and was
already tested experimentally on rodents (rats and rabbits)
and non-rodents (dogs and sheep) [2-5]. In humans, the
fibrin sealant was tested in a autologous skin graft of
the nasogenian sulcus as donor site to repair a nasal
surgical wound, in the immobilization of free periodontal
gingival grafts in lower premolars, in the fixation of a
conjunctive tissue graft for the correction of gingival
marginal tissue recessions and in the treatment of chronic
venous ulcers [6-10].Correspondence: rseabra@cevap.unesp.br
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unless otherwise stated.Recently, we have investigated the effects of the fibrin
sealant as a scaffold for mesenchymal stem cells in order
to demonstrate the ability of cells to interact with the
biological microenvironment [11]. We observed that
the product did not affect cell adhesion, proliferation or
differentiation and allowed the adherence and growth
of mesenchymal stem cells on its surface. Hoechst
33342 and propidium iodide staining demonstrated the
viability of mesenchymal stem cells in contact with the
fibrin sealant and the ability of the biomaterial to maintain
cell survival. We concluded that the new biomaterial is a
three-dimensional scaffolding candidate that is capable
of maintaining cell survival without interfering with
differentiation, and might also be useful in drug delivery.
The fibrin sealant has a low production cost, does not
transmit infectious diseases from human blood and has
properties of a suitable scaffold for stem cells because it
permits the preparation of differentiated scaffolds that are
suitable for every need.
Similarly, de la Puente et al. [12-14] developed an autolo-
gous fibrin scaffold: cheaper, easy to use, natural (with
physiological concentrations of fibrinogen), implantable,
highly available and with low fibrinogen concentrations.
The key point to this model is that no fibrinogen con-
centration techniques, such as cryoprecipitation or other
chemical methods, are used. This system is suitable both
for cell culture and cell differentiation. Autologous blood
is collected, centrifuged to separate it from the plasma
(physiological concentrations in plasma are 2–4 mg/mL)
and frozen at −40°C until used. Accordingly, more natural
and fewer modified fibrins are used and the nature of the
fibrin (with its physiological concentrations) is preserved.
The authors concluded that the structuring and develop-
ment of the scaffold is a key point for cell culture because
scaffolds of autologous fibrin offer an important alterna-
tive due to their low fibrinogen concentrations, which are
more suitable for cell growth [12-14].al Ltd. This is an Open Access article distributed under the terms of the Creative
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http://www.jvat.org/content/20/1/31The results of de la Puente et al. [12-14] are in dis-
agreement with those of Gasparotto et al. [11], since the
scaffold of the latter is of animal origin (constituted by
fibrinogen extracted from buffalos through the cryo-
precipitation technique), contains elevated fibrinogen
concentrations, permits good growth of cells in a new
biomaterial, and poses no risk of transmitting infectious
diseases by means of human blood. Although both sealants
(autologous and heterologous) are natural, biodegradable,
bio-absorbent, non-toxic and non-immunogenic, future
comparative studies using human stem cells should be
carried out to clarify these points.
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